Table 2.
Multivariable analysis for clinical outcome for patienets with AML(OS).
| Overll survival |
||
| Variables | P-value | HR (95%CI) |
| MAP4K1 expression (High vs Low) | 0.033 | 1.686(1.043,2.726) |
| Age | 0.063 | 1.016(0.999,1.032) |
| WBC | 0.525 | 1.001(0.997,1.006) |
| BM blast | 0.039 | 1.013(1.001,1.026) |
| Karyotype-risk group | ||
| Intermediate vs. favorable | 0.646 | 0.757(0.230,2.491) |
| Poor vs. favorable | 0.584 | 1.546(0.324,7.375) |
| Gene mutation | ||
| NPM1 | 0.243 | 0.700(0.385,1.273) |
| FLT3ITD | 0.040 | 1.747(1.026,2.975) |
| DNMT3a | 0.011 | 2.211(1.201,4.071) |
| IDH1 | 0.839 | 1.110(0.405,3.042) |
| IDH2 | 0.677 | 1.183(0.536,2.612) |
| Treatment protocols | ||
| IA vs.DA | 0.929 | 1.032(0.513,2.078) |
| HAA vs.DA | 0.823 | 0.910(0.397,2.084) |
HR hazard ratio;CI confidence interval;
*Multivariate analysis were performed by Cox proportional hazards models with the backward likehood stepwise procedures.